There are currently 182 clinical trials in Torrance, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Harbor - UCLA Medical Center, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance Memorial Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
NCT06151197
Recruiting
This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Endo Site 61, Torrance, California
Conditions: Plantar Fibromatosis, Ledderhose Disease
Register for Updates
Study of Osimertinib with Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
NCT05401110
Recruiting
The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC, Torrance, California
Conditions: Non Small Cell Lung Cancer, Lung Cancer
Register for Updates
Pragmatic Trial of Psilocybin Therapy in Palliative Care
NCT05403086
Recruiting
This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California
Conditions: Demoralization
Register for Updates
A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).
NCT06067828
Recruiting
This study will investigate the effect of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) compared with Placebo MDI, and Budesonide and Formoterol Fumarate (BFF) MDI on isotime inspiratory capacity (IC) and exercise endurance time.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
03/03/2025
Locations: Research Site, Torrance, California
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
NCT06615557
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/03/2025
Locations: Vistagen Clinical Site, Torrance, California
Conditions: Social Anxiety Disorder (SAD)
Register for Updates
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281
Recruiting
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/02/2025
Locations: LA BioMed Harbor UCLA Med Cenr, Torrance, California +1 locations
Conditions: Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Register for Updates
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581
Recruiting
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California
Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Register for Updates
Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections
NCT02134301
Recruiting
The purpose of this Phase 1 trial is to evaluate the pharmacokinetics, safety and tolerability of oritavancin in patients \<18 years old with a confirmed or suspected bacterial infection.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
02/27/2025
Locations: UCLA Harbor Medical Center, Torrance, California
Conditions: Gram Positive Bacterial Infections
Register for Updates
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
02/27/2025
Locations: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California +1 locations
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Register for Updates
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
NCT02687906
Recruiting
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections
Gender:
ALL
Ages:
17 years and below
Trial Updated:
02/27/2025
Locations: Los Angeles Biomedical Research Institute, Torrance, California
Conditions: Bacterial Infections
Register for Updates
A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
NCT05494593
Recruiting
The main aim of this study is to evaluate the ability of a prophylactic immune tolerizing regimen (ITR) to prevent or reduce the development of high titer anti-idursulfase antibodies in treatment-naïve participants with Hunter syndrome. In this open label, single arm study, all participants will receive ELAPRASE treatment and a prophylactic ITR. Participants will be treated with ELAPRASE for up to 104 weeks. The prophylactic ITR will start 1 day prior to the start of ELAPRASE. The prophylactic... Read More
Gender:
MALE
Ages:
6 years and below
Trial Updated:
02/27/2025
Locations: The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center, Torrance, California
Conditions: Mucopolysaccharidosis (MPS), Hunter Syndrome
Register for Updates
A Phase 1, First in Human Study of TORL-4-500 in Patients with Advanced Cancer
NCT06005740
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Torrance Memorial Physician Network, Torrance, California
Conditions: Advanced Solid Tumor, Hepatocellular Carcinoma
Register for Updates